Cannathemag
  • News
  • Magazine
  • Advertising
  • About Us
  • Language Services
  • Contacts
  • Search
  • CZ
Facebook Instagram

European Parliament Passes Cannabis Resolution, Joins WHO in Supporting Medical Marijuana

14. February 2019 | Rubrika: Breaking News

Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union.

While non-binding, the resolution seeks to incentivize European nations to increase access to medical marijuana, prioritizing scientific research and clinical studies. Same as the WHO’s recommendation, the European Parliament’s resolution shows how wide support for cannabis legalization is, but does not change any actual laws on the international or local levels.

Governments can no longer turn their heads to the opportunity it delivers,

“The EU Parliament is just the latest voice to recognize the medical value of cannabis and the benefits of regulation over prohibition,” Tom Angell, Forbes contributor and publisher of Marijuana Moment, told me. “I’m hopeful that the growing chorus in favor of reform will spur action by nations to change their policies and improve access for patients who need this medicine.”

The Details

After evaluating how the European Union could potentially support quality research in relation to marijuana-based medicines, establishing “standards for non-pharmaceutical medical cannabis to ensure consumer safety,” the members of the European Parliament voted on a resolution that calls on the Commission on use of cannabis for medicinal purposes and the states member of the European Union to “address the regulatory, financial and cultural barriers” that stunted scientific research on the cannabis and its medical uses.

In addition, the Commission and MEPs said it’s important to “define the conditions required to enable creditable, independent scientific research based on a wide range of material to be conducted into the use of cannabis for medicinal purposes.”

Finally, they pointed out the need for an improvement in equal access to cannabis-based medicines and the right case-specific therapies. “It is essential that they be provided with comprehensive information about the full spectrum profiles of the plant strains used in the medication provided,” the resolution reads, calling for a close collaboration with the WHO.

The Cannabis Community Reacts

Interested in hearing what the cannabis community had to say, I reached out to cannabis industry participants in different geographies, from Asia, to Europe, to the Americas. Evan Eneman, CEO of ELLO, leader of the MGO/ELLO Alliance and founder of Sands Lane Capital, said that, “Once again, our friends around the world see the medical benefit and potential of the plant, and are working towards a better understanding of what can be in earnest.”

Eneman added he’s looking forward to the U.S. taking a similar approach, so that research and development of cannabis based therapies and consumables for all its various use cases can continue to advance.

Aras Azadian, CEO of multi-national cannabis company Avicanna, also applauded the European Parliament’s decision to change it position on cannabis and cannabinoids. “This will help facilitate and expedite the well required safety and efficacy studies on cannabinoid solutions beyond the initial markets such as Canada and Israel (…) There is an ongoing concern of the toxic and inefficacious products being offered as medicine that will be limited with the entrance of qualified studies.”

Same as the WHO’s recommendation, the European Parliament’s resolution shows how wide support for cannabis legalization is.

Meanwhile, Israel-based Oren Todoros, co-founder at CannaImpact, highlighted the economic opportunity behind cannabis and the increasing recognition of this potential. “Governments (…) can no longer turn their heads to the opportunity it delivers,” he said.

Jonas Duclos is the CEO of Switzerland-based JKB Research, the company behind CBD420, a line of low-THC cannabis products sold across tobacco shops and other “regular” stores across Europe. Duclos qualified the move as relieving. “More and more key global actors are recognizing the therapeutic effects of cannabis,” he said. However, for him, the really important question is: when will lawmakers consider moving forward with actual legislation? And, once they do, how will the regulations look like?

“We know support and political capital will grow, but these are the details that will determine where the industry heads in the next years,” he ended.

Author: Javier Hasse

Source: Forbes

Ohodnoťte tento článek
cannabis researchinternational cannabis policyLegalizationmedical cannabis

You might like

  • press conferece Breaking News

    New campaign for rational cannabis regulation supports not only homegrowing but also regulated market

  • Breaking News

    Biobizz World Wide Organics and Juju Royal – Julian Marley launch their new 100% organic brand, embracing the Rastafarianessence

  • conference discussion Breaking News

    Hemp & Industry conference in Prague shows that hemp has a huge potential

Write comment Cancel

Search

Latest News

  • Source: Pexels.com

    Cannabis Suppositories: For Which Ailments?

    7. July 2025
  • Zdroj: unsplash.com

    Superior Treatment: Cannabis Extracts in Suppositories

    19. May 2025
  • Europe’s Largest Cannabis B2B Conference Is Coming Back To Berlin in One Week!

    22. April 2025
  • Source: Cannabis Embassy

    Centenary of Cannabis Prohibition: Global Cannabis History Year

    27. February 2025
Facebook YouTube SoundCloud
  • Advertising
  • Magazine
  • About Us
  • Contacts
  • Terms and Conditions

CANNABIS THERAPY

Magazine about medical uses of cannabis. For patients, health professionals as well as general public. Free of charge.

Contact: office@konomag.cz

Tel.: +420 737 300 375

CATEGORIES

  • Advice
  • Breaking News
  • Experimental Treatment
  • Health
  • Inspiration
  • Interviews
  • Leaves of Grass
  • News
  • Pharmacopeia
  • Pharmacopoeia
  • Press Release
  • Research Reports
  • Uncategorized
  • Veterinary Medicine

LATEST NEWS

  • Source: Pexels.com

    Cannabis Suppositories: For Which Ailments?

    7. July 2025
  • Zdroj: unsplash.com

    Superior Treatment: Cannabis Extracts in Suppositories

    19. May 2025

SEARCH

Follow us

Facebook Instagram
  • © 2018-25 CANNABIS THERAPY magazine. All rights belong to their respective owners. Without their written consent it is prohibited to use parts or whole works in any way, particularly spreading and copying, mechanically or electronically, in English, Czech or any other language.

  • Cannathemag

    Manage consent to cookies and confirm your age
    We use technologies such as cookies to store and/or access device information. We do this to improve your browsing experience and display personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or a unique ID on this website. Disagreeing or withdrawing consent may adversely affect certain features and functions.

    This website also requires you to be of legal age. By accepting your preferences, you verify you are at least 18 years old.
    Functional Always active
    Technical storage or access is absolutely necessary for the legitimate purpose of enabling the use of a specific service that the subscriber or user has expressly requested, or for the sole purpose of carrying out the transmission of a message via an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    Technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    Technical storage or access is necessary to create user profiles in order to send advertising or track the user across a website or several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    Show preferences
    {title} {title} {title}
    Are you 18+?

    This website requires you to be of legal age. By clicking Yes, you verify you are at least 18 years old.